Dr. Reddy’s Laboratories and Coya Therapeutics have entered into a development and license agreement for the development and commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Under the terms of the agreement, Dr. Reddy’s has an exclusive license to commercialize the treatment, a proprietary co-pack kit containing a combination of low dose IL-2 and CTLA-4 Ig (abatacept) for ALS in the United States, Canada, the European Union, and the United Kingdom.